Skip to content

Trial Summary

A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of Ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer.



ACTRN/NCT /ethics:


Scientific title:

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Sponsor / Cooperative group:

Novartis Pharmceuticals

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2018-12-07
Anticipated End Date-

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Phone08 8204 4830
Principal InvestigatorDr Sina Vatandoust
Recruitment StatusRecruiting